Cargando…
Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649281/ http://dx.doi.org/10.1186/2051-1426-3-S2-P341 |
| _version_ | 1782401323685117952 |
|---|---|
| author | Pandha, Hardev Harrington, Kevin Ralph, Christy Melcher, Alan Grose, Mark Shafren, Darren |
| author_facet | Pandha, Hardev Harrington, Kevin Ralph, Christy Melcher, Alan Grose, Mark Shafren, Darren |
| author_sort | Pandha, Hardev |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4649281 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46492812015-11-24 Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients Pandha, Hardev Harrington, Kevin Ralph, Christy Melcher, Alan Grose, Mark Shafren, Darren J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4649281/ http://dx.doi.org/10.1186/2051-1426-3-S2-P341 Text en Copyright © 2015 Pandha et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Pandha, Hardev Harrington, Kevin Ralph, Christy Melcher, Alan Grose, Mark Shafren, Darren Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title | Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title_full | Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title_fullStr | Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title_full_unstemmed | Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title_short | Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients |
| title_sort | phase i/ii storm study: intravenous delivery of a novel oncolytic immunotherapy agent, coxsackievirus a21, in advanced cancer patients |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649281/ http://dx.doi.org/10.1186/2051-1426-3-S2-P341 |
| work_keys_str_mv | AT pandhahardev phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients AT harringtonkevin phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients AT ralphchristy phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients AT melcheralan phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients AT grosemark phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients AT shafrendarren phaseiiistormstudyintravenousdeliveryofanoveloncolyticimmunotherapyagentcoxsackievirusa21inadvancedcancerpatients |